Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

Acute Myeloid Leukemia Clinical Trial

Official title:

A Pilot Study to Determine the Safety and Efficacy of Incorporating Hyperbaric Oxygen Therapy Into RIC Fludarabine and Melphalan and Allogeneic Hematopoietic Stem/Progenitor Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03964506
• Other study ID #: UBMT-19163
• Status: Recruiting
• Phase: Early Phase 1
• Start date: July 1, 2020
• Est. completion date: March 1, 2025

Study information

• Verified date: May 2024
• Source: University of Rochester
• Contact: Regulatory Coordinator
• Phone: (585) 276-7078
• Email: Lisa_Metzger[@]URMC.Rochester.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if hyperbaric oxygen therapy is safe in the setting of stem cell transplantation. This study will also determine if hyperbaric oxygen therapy improves engraftment, graft versus host disease, neutrophil count, and incidence and severity of mucositis (inflammation of the mouth or gut) and infection. This study has two cohorts. The first cohort is subjects with acute myeloid leukemia (AML) or Myelodysplastic Syndrome (MDS). The second cohort is subjects with chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), chronic monocytic leukemia, chronic neutrophilic leukemia (CNL), myelofibrosis, and myelodysplastic/myeloproliferative (MDS/MPN) overlap syndrome. The first cohort has completed the recruitment so only the second cohort will be recruited.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: March 1, 2025
• Est. primary completion date: March 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Voluntary written informed consent
• Men or women, age = 18 years of age, with upper limit of 75 years old.
• Subjects with acute myeloid leukemia (AML) or Myelodysplastic Syndrome (MDS) for cohort 1.
• Subjects with chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), CML, chronic neutrophilic leukemia (CNL), myelofibrosis, and myelodysplastic/myeloproliferative (MDS/MPN) overlap syndrome for cohort 2.
• Karnofsky performance status (KPS) of = 70%
• Patients should have New York Heart Association (NYHA) Functional Classification, Class I (ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain) or Class II (ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain).
• Adequate hepatic, renal, cardiac and pulmonary function to be eligible for transplant. Minimum criteria include: Hepatic: ALT, AST < 4x IULN and serum total bilirubin = 2.0 mg/dL; Renal: serum creatinine: = 2.0 mg/dL; Left ventricular ejection fraction = 45% measured by 2D-ECHO or MUGA scan; EKG with no clinically significant arrhythmia; FEV1, FVC and DLCO = 50% of predicted value (corrected to serum hemoglobin)
• Women of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days following completion of therapy. Should a woman or partner become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician and the investigator immediately.
• A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: Has not undergone a hysterectomy or bilateral oophorectomy; or Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
• Women of child-bearing potential should have a negative urine or serum pregnancy test within 4 weeks of starting preparative regimen

Exclusion Criteria:

• Pregnant or breastfeeding
• Severe chronic obstructive pulmonary disease requiring oxygen supplementation
• History of spontaneous pneumothorax, prior chest surgery requiring thoracotomy or direct chest irradiation to the lungs
• Evidence of pneumothorax or significant pulmonary fibrosis on chest imaging within 60 days of transplant.
• Active malignancy excluding AML, MDS, CMML, aCML CML, CNL, MF and MDS/MPN overlap syndrome.
• Active ear/sinus infection. Patients with chronic sinusitis or sinus headaches are excluded unless cleared by ear, nose, and throat specialist.
• Recent sinus surgery (within the last 5 years).
• Ear surgery excluding myringotomy or ear tubes
• Subjects must agree to refrain from active tobacco or e-cigarette use 72 hours prior to transplant until complete transplant recovery. Nicotine replacement therapy is allowed.
• Claustrophobia
• History of recurrent seizures within 5 years of study enrollment.
• Uncontrolled asthma
• Uncontrolled viral or bacterial infection at the time of study enrollment
• Active or recent (prior 6 months) invasive fungal infection without interdisciplinary (ID) consult and approval
• Patients who had intrathecal chemotherapy within 2 weeks of starting preparative regimen or cranial irradiation within 4 weeks of starting preparative regimen

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Atypical Chronic Myeloid Leukemia
• Chronic Myelomonocytic Leukemia
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
• Leukemia, Myelomonocytic, Chronic
• Leukemia, Myelomonocytic, Juvenile
• Myelodysplastic Syndromes
• Myelodysplastic-Myeloproliferative Diseases
• Myelodysplastic/Myeloproliferative Neoplasm
• Myelofibrosis
• Myeloproliferative Disorders

Intervention

Drug:
• Hyperbaric oxygen
Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant

Locations

Country	Name	City	State
United States	Wilmot Cancer Institute, University of Rochester	Rochester	New York

Sponsors (1)

Lead Sponsor	Collaborator
Omar Aljitawi

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immediate safety of hyperbaric oxygen therapy prior to allogeneic stem cell transplantation in Cohort 1	Treatment-limiting toxicities will be assessed 24-hours post-hyperbaric oxygen therapy.	24 hours
Primary	Immediate safety of hyperbaric oxygen therapy prior to allogeneic stem cell transplantation in cohort 2	Treatment-limiting toxicities will be assessed 24-hours post-hyperbaric oxygen therapy.	24 hours
Primary	Long term safety of hyperbaric oxygen therapy prior to allogeneic stem cell transplant in Cohort 1	Possible long-term effects of hyperbaric oxygen therapy treatment prior to allogeneic peripheral blood stem cell transplant will be assessed at day +100 post-transplant	100 days
Primary	Long term safety of hyperbaric oxygen therapy prior to allogeneic stem cell transplant in Cohort 2	Possible long-term effects of hyperbaric oxygen therapy treatment prior to allogeneic peripheral blood stem cell transplant will be assessed at day +100 post-transplant	100 days
Secondary	Time to neutrophil recovery in Cohort 1	based on the patient having achieved three consecutive days of Absolute Neutrophile Count (ANC) = 500/microliter	100 days
Secondary	Time to neutrophil recovery in Cohort 2	based on the patient having achieved three consecutive days of Absolute Neutrophile Count (ANC) = 500/microliter	100 days
Secondary	Time to complete donor chimerism in Cohort 1	Bone marrow chimerism will be checked on day +30 and day +100 Bone Marrow (BM) samples according to our standard of care	100 days
Secondary	Time to complete donor chimerism in Cohort 2	Bone marrow chimerism will be checked on day +30 and day +100 Bone Marrow (BM) samples according to our standard of care	100 days
Secondary	Incidence of mucositis in Cohort 1		100 days
Secondary	Incidence of graft versus host disease in Cohort 1		100 days
Secondary	Incidence of infection in Cohort 1		100 days
Secondary	Incidence of mucositis in Cohort 2		100 days
Secondary	Incidence of infection in Cohort 2		100 days
Secondary	Incidence of graft versus host disease in Cohort 2		100 days